THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, you should consult with your independent. | June 12, 2023
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) Director Linda Grais bought 10,000 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were bought at an average cost of $2.45 per share, with a total value of $24,500.00. Following the completion of the transaction, the director now owns 10,000 shares […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) Director Linda Grais acquired 10,000 shares of the business’s stock in a transaction on Monday, May 15th. The stock was purchased at an average cost of $2.45 per share, with a total value of $24,500.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s […]